If you believed all this and bought in... do you still believe.
Remember the stock was up 12% three days into the new year.
From Amy Baldwin 1/28/13
I look for big things from NeoStem this year due to its ownership of stem cell manufacturer and developer Progenitor Cell Therapy (PCT) plus its own ongoing trials of what could be two very successful and very profitable stem cell therapies being developed by the company's other divisions.
From Brian Nichols 1/7/13
Therefore, in this article I am looking at the best of the best, those developments that could have industry changing effects, and could open new doors in the immediate future. Specifically, I am looking at the leader in cell therapy, NeoStem (NBS), a company that had a truly breakthrough year.
From Amy Baldwin 1/2/13 Headline With Osiris Overvalued, NeoStem Is A Better Buy
The reason that NeoStem is my choice as the best value play in cell therapy is because of its diversity, its growth, and its valuation. The company is trading at just over three times next year's sales
Brian WIlson 2/13/13
Overall, Neostem is quite the oddball of the stem cell sector but it is relatively inexpensive at a $100 million valuation, and offers great diversity in terms of its sources of revenue. I think it could move much higher this year if the top-line growth continues as the company reports financial figures in future quarters.
A. John Hodge 1/22/13
All three still have good entry prices, though of the three I would choose NeoStem as my first choice due to its revenue stream with its PCT manufacturing, its stem cell therapies that have shown promise in early testing, and due to my opinion of it being an undervalued company.
NBS is a penny stock and as such it is treated from big boys. Small retail investors have not much control over the price. Its classy example of either you do your DD and believe in long term potential or drop it. Looking on a daily basis at the price action can only confuse you as these are not common folks who are causing massive price fluctuations. Those are traders who dont have huge interest in holding company long term. I agree with above authors, this is a solid pick despite bleeding for the past few days.